 That certainly should encourage us to look at more prevention efforts, how those are being marketed. We don't want those marketed looking like candies to children. We also are seeing some of the opioids that are used for prevention that we think about with maintenance, methadone, buprenorphine. In the pediatric age group, the same thing. We need to be careful as to what access children have to those.